The potential for drug interactions with statin therapy in Ireland

Irish Journal of Medical Science

Volumn 169, Issue 3, 2000, Pages 176-179

  Heerey, A ^a   Barry, M ^a   Ryan, M ^a   Kelly, A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CALCIUM ANTAGONIST; CARBAMAZEPINE; CERIVASTATIN; CLARITHROMYCIN; DICLOFENAC; DILTIAZEM; ERYTHROMYCIN; ESTRADIOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MEFENAMIC ACID; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PRAVASTATIN; RIFAMPICIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ADVERSE DRUG REACTION; ARTICLE; DATA ANALYSIS; DRUG CHOICE; DRUG COMPETITION; DRUG INHIBITION; DRUG METABOLISM; HOSPITAL ADMISSION; HUMAN; IRELAND; LIVER METABOLISM; MAJOR CLINICAL STUDY; PRESCRIPTION;

EID: 0034476733     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03167690     Document Type: Article

References (20)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
6. Pharmacoeconomics of lipid lowering therapy in Ireland
7. Metabolism and drug interactions of 3′-hydroxy-3′-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
8. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
10. 'Fire and forget?' - Pharmacological considerations in coronary care
11. The human hepatic cytochromes P450 involved in drug metabolism
12. Comparisons of properties of four inhibitors of 3-hydroxy-3 methylglutaryl-coenzyme A reductase
13. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
14. Metabolic disposition of simvastatin in patients with T-tube drainage
15. Simvastatin but not pravastatin, is very susceptible to interact with the CYP 3A inhibitor itraconazole
16. Atorvastatin pharmacokinetic interactions with other CYP 3A4 substrates: Erythromycin and ethinylestradiol
17. Effect of itraconazole on the pharmacokinetics of atorvastatin
18. Biotransformation of fluvastatin sodium in humans
19. In vivo inhibition profile of cytochrome P450 (CYP 2C9) by fluvastatin
20. Gastrointestinal absorption of pravastatin in healthy subjects